Roth Mkm Begins Coverage on Verona Pharma (NASDAQ:VRNA)

2 days ago · Shares of VRNA opened at $45.20 on Friday. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. Verona Pharma has a 12 month …

$45.20
OFF

Roth Mkm Begins Coverage On Verona Pharma (NASDAQ:VRNA)

2 weeks from now

2 days ago · Shares of VRNA opened at $45.20 on Friday. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. Verona Pharma has a 12 month …

etfdailynews.com

$68
OFF

Verona Pharma Initiated With A Buy At Roth MKM - Markets Insider

2 weeks from now

5 days ago · Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma with a Buy rating and $68 price target The firm says its investment thesis is driven by …

businessinsider.com

$68.00
OFF

Verona Pharma Plc (NASDAQ:VRNA) Given Consensus Rating Of …

2 weeks from now

4 days ago · Finally, Roth Mkm initiated coverage on Verona Pharma in a report on Friday. They set a “buy” rating and a $68.00 target price on the stock. Get Verona Pharma alerts: View Our …

tickerreport.com

$45.20
OFF

Roth Mkm Begins Coverage On Verona Pharma (NASDAQ:VRNA)

2 weeks from now

3 days ago · Shares of NASDAQ VRNA opened at $45.20 on Friday. Verona Pharma has a twelve month low of $11.39 and a twelve month high of $51.80. The company has a current …

defenseworld.net

$68.00
OFF

Verona Pharma (NASDAQ:VRNA) Raised To Strong-Buy At Roth …

2 weeks from now

3 days ago · Finally, Roth Mkm began coverage on Verona Pharma in a research note on Friday. They issued a “buy” rating and a $68.00 price target on the stock. Seven research analysts …

defenseworld.net

$68.00
OFF

Verona Pharma Plc (NASDAQ:VRNA) Given Consensus

2 weeks from now

4 days ago · Roth Mkm initiated coverage on shares of Verona Pharma in a research note on Friday. They issued a "buy" rating and a $68.00 target price for the company. HC Wainwright …

marketbeat.com

$68
OFF

Roth MKM Initiates Coverage On Verona Pharma With Buy Rating, …

2 weeks from now

5 days ago · Roth MKM analyst Boobalan Pachaiyappan initiates coverage on Verona Pharma (NASDAQ:VRNA) with a Buy rating and announces Price Target of $68.

sahmcapital.com

19%
OFF

Verona Pharma (VRNA) Stock Forecast And Price Target 2025

2 weeks from now

Learn why top analysts are making this stock forecast for Verona Pharma at MarketBeat. ... Roth Mkm. 1 of 5 stars : Initiated Coverage: Buy: $68.00 +47.19%: 1/8/2025: Wells Fargo & …

marketbeat.com

FAQs about Roth Mkm Begins Coverage on Verona Pharma (NASDAQ:VRNA) Coupon?

Is Verona Pharma a good stock to buy?

The firm issued a buy rating and a $68.00 price objective on the stock. Several other equities analysts have also commented on the stock. Wells Fargo & Company raised their target price on shares of Verona Pharma from $64.00 to $74.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. ...

What is the price target for Verona Pharma (vRNA)?

The highest price target for VRNA is $74.00, while the lowest price target for VRNA is $33.00. The average price target represents a forecasted upside of 14.23% from the current price of $44.27. Enter your email address to receive the latest news and analysts' ratings for Verona Pharma and its competitors. ...

What is the price target for Verona Pharma plc - depositary receipt ()?

As of December 23, 2024, the average one-year price target for Verona Pharma plc - Depositary Receipt () is $47.94/share. The forecasts range from a low of $36.36 to a high of $67.20. The average price target represents an increase of 5.90% from its latest reported closing price of $45.27 / share. ...

When did Verona Pharma go public?

Verona Pharma (VRNA) went public on Thursday, April 27th 2017 through an IPO. The company raised $61 million by issuing 4,500,000 shares at a price of $13.49 per share. ...

Why is boobalan Pachaiyappan buying Verona Pharma (vRNA)?

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA). Boobalan Pachaiyappan has given his Buy rating due to a combination of factors influencing Verona Pharma’s market position and potential growth. ...

Who owns Verona Pharma?

Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock worth $75,000 after purchasing an additional 529 shares during the period. Diversify Advisory Services LLC bought a new position in Verona Pharma during the third quarter worth $169,000. ...